A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response
Yadira Lobaina(Centro de Ingeniería Genética y Biotecnología), Lisset Hermida(Centro de Ingeniería Genética y Biotecnología), Panchao Ai(Zhejiang Yongning Pharma (China)), Gerardo Guillén(Hunan City University), Changyuan Tan(Zhejiang Yongning Pharma (China)), Ke Yang(Army Medical University), Glay Chinea, Wen Li(Zhejiang Yongning Pharma (China)), Ricardo Silva(Centro de Ingeniería Genética y Biotecnología), Rong Chen(Zhongda Hospital Southeast University), Yaqin Lan(Zhejiang Yongning Pharma (China)), Edith Suzarte(Centro de Ingeniería Genética y Biotecnología), Alexis Musacchio(Instituto Cajal), Yasser Perera(Construction Development (Qatar))
Cited by 6
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134